Jyong Biotech

Jyong Biotech FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Jyong Biotech (MENS) as of Nov 20, 2026 is 65.10 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 120.04 % — a change of -45.76% (lower).

FCF Conversion

65.10 %

YoY

-45.76%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Jyong Biotech is 2025 65.10 % . FCF Conversion Rate (FCF/EBITDA) of Jyong Biotech was 2024 120.04 % . It decreases by -45.76% lower compared to the previous year.

The Jyong Biotech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
61.33 USD
Jan 1, 2021
50.52 USD
Jan 1, 2022
48.52 USD
Jan 1, 2023
59.11 USD
Jan 1, 2024
120.04 USD
Jan 1, 2025
65.10 USD
The Jyong Biotech FCF Conversion history
YEARFCF ConversionYoY
65.10 %-45.76%
120.04 %+103.07%
59.11 %+21.83%
48.52 %-3.96%
50.52 %-17.61%
61.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jyong Biotech Stock analysis

What does Jyong Biotech do? Jyong Biotech Ltd. develops and commercializes plant-derived biotechnology products, focusing on urinary system diseases. The company's primary product is MCS-2, a botanical drug candidate for benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS), and PCP, a clinical-stage botanical drug candidate for prostate cancer prevention. These products target markets in the United States, European Union, and Asia. The firm generates revenue through the development and eventual commercialization of these innovative botanical drug candidates, with MCS-2 and PCP representing key stages in its pipeline. Jyong Biotech's business model centers on advancing its botanical drug candidates through clinical and preclinical stages. The company employs 29 full-time employees to manage research, development, and commercialization efforts. Its focus on plant-derived treatments for urinary system diseases positions it to serve patients and healthcare providers in the U.S., EU, and Asian markets. The firm's revenue streams will primarily come from the successful development and sale of MCS-2 and PCP once they reach commercialization. The company's product portfolio includes MCS-2, PCP, and other preclinical-stage botanical drug candidates. These products are developed for specific medical conditions, with MCS-2 targeting BPH/LUTS and PCP targeting prostate cancer prevention. The firm's strategy involves leveraging its botanical drug development expertise to enter key global markets. Revenue will be generated once these products are approved and sold in the U.S., EU, and Asia. Jyong Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jyong Biotech stock

FCF Conversion Rate (FCF/EBITDA) of Jyong Biotech is 65.10 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Jyong Biotech changed from 120.04 % to 65.10 %, representing a -45.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Jyong Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Jyong Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Jyong Biotech

All Key Metrics — Jyong Biotech